The global Bio Pharma Buffer market size was valued at US$ 994 million in 2024 and is forecast to a readjusted size of USD 1591 million by 2031 with a CAGR of 7.0% during review period.
A buffer solution is comprised of a weak conjugate acid-base pair, for example, a weak acid and its conjugate base, or a weak base and its conjugate acid. Small quantities of other acids or bases are neutralized when added to the solution, and as a result, the solution resists changes in pH. Solutions with stable pH are required for the processing of protein-based biologic APIs because of their sensitivity to changes in pH. The stable pH range and capacity (the amount of acid/base that can be added without a change in pH) of a buffer are determined by the conjugate acid-base pair.
Most purification steps for downstream processing of biologics require buffers to equilibrate, condition, wash, elute, or concentrate the product. They are used in product isolation and purification steps to facilitate protein capture and polishing and also in the filtration process for the removal of viruses or depyrogenation. Aqueous solutions are also required for cleaning and disinfecting downstream processing equipment, such as chromatography matrices and membrane filtration systems. The main equipment involved in downstream processing with buffers includes mixers for buffer preparation, as well as equipment for purification, including packed-bed chromatography systems, fluidized beds, ultrafiltration and diafiltration membranes, microfiltration membranes, depth filtration cartridges, and virus-removal systems.
The key players are Avantor, Alfa Aesar (Thermo Fisher), Merck, Lonza, Bio-Rad, BD, GE, Healthcare, Promega Corporation, Hamilton Company, XZL BIO-TECHNOLOGY, SRL and so on. According to the revenue of these companies, we can know that the Bio Pharma Buffer industry is relative concentrated. Because the top 6 companies have more than 70% market share.
This report is a detailed and comprehensive analysis for global Bio Pharma Buffer market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Bio Pharma Buffer market size and forecasts, in consumption value ($ Million), sales quantity (K Liter), and average selling prices (USD/Liter), 2020-2031
Global Bio Pharma Buffer market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Liter), and average selling prices (USD/Liter), 2020-2031
Global Bio Pharma Buffer market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Liter), and average selling prices (USD/Liter), 2020-2031
Global Bio Pharma Buffer market shares of main players, shipments in revenue ($ Million), sales quantity (K Liter), and ASP (USD/Liter), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Bio Pharma Buffer
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Bio Pharma Buffer market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Avantor, Alfa Aesar (Thermo Fisher), Merck, Lonza, Bio-Rad, BD, GE Healthcare, Promega Corporation, Hamilton Company, XZL BIO-TECHNOLOGY, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Bio Pharma Buffer market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Phosphates Type
Acetates Type
TRIS Type
Others
麻豆原创 segment by Application
Research Institution
Pharmaceutical Industry
Others
Major players covered
Avantor
Alfa Aesar (Thermo Fisher)
Merck
Lonza
Bio-Rad
BD
GE Healthcare
Promega Corporation
Hamilton Company
XZL BIO-TECHNOLOGY
SRL
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Bio Pharma Buffer product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Bio Pharma Buffer, with price, sales quantity, revenue, and global market share of Bio Pharma Buffer from 2020 to 2025.
Chapter 3, the Bio Pharma Buffer competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Bio Pharma Buffer breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Bio Pharma Buffer market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Bio Pharma Buffer.
Chapter 14 and 15, to describe Bio Pharma Buffer sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Bio Pharma Buffer Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Phosphates Type
1.3.3 Acetates Type
1.3.4 TRIS Type
1.3.5 Others
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Bio Pharma Buffer Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Research Institution
1.4.3 Pharmaceutical Industry
1.4.4 Others
1.5 Global Bio Pharma Buffer 麻豆原创 Size & Forecast
1.5.1 Global Bio Pharma Buffer Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Bio Pharma Buffer Sales Quantity (2020-2031)
1.5.3 Global Bio Pharma Buffer Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Avantor
2.1.1 Avantor Details
2.1.2 Avantor Major Business
2.1.3 Avantor Bio Pharma Buffer Product and Services
2.1.4 Avantor Bio Pharma Buffer Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Avantor Recent Developments/Updates
2.2 Alfa Aesar (Thermo Fisher)
2.2.1 Alfa Aesar (Thermo Fisher) Details
2.2.2 Alfa Aesar (Thermo Fisher) Major Business
2.2.3 Alfa Aesar (Thermo Fisher) Bio Pharma Buffer Product and Services
2.2.4 Alfa Aesar (Thermo Fisher) Bio Pharma Buffer Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Alfa Aesar (Thermo Fisher) Recent Developments/Updates
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business
2.3.3 Merck Bio Pharma Buffer Product and Services
2.3.4 Merck Bio Pharma Buffer Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Merck Recent Developments/Updates
2.4 Lonza
2.4.1 Lonza Details
2.4.2 Lonza Major Business
2.4.3 Lonza Bio Pharma Buffer Product and Services
2.4.4 Lonza Bio Pharma Buffer Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Lonza Recent Developments/Updates
2.5 Bio-Rad
2.5.1 Bio-Rad Details
2.5.2 Bio-Rad Major Business
2.5.3 Bio-Rad Bio Pharma Buffer Product and Services
2.5.4 Bio-Rad Bio Pharma Buffer Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Bio-Rad Recent Developments/Updates
2.6 BD
2.6.1 BD Details
2.6.2 BD Major Business
2.6.3 BD Bio Pharma Buffer Product and Services
2.6.4 BD Bio Pharma Buffer Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 BD Recent Developments/Updates
2.7 GE Healthcare
2.7.1 GE Healthcare Details
2.7.2 GE Healthcare Major Business
2.7.3 GE Healthcare Bio Pharma Buffer Product and Services
2.7.4 GE Healthcare Bio Pharma Buffer Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 GE Healthcare Recent Developments/Updates
2.8 Promega Corporation
2.8.1 Promega Corporation Details
2.8.2 Promega Corporation Major Business
2.8.3 Promega Corporation Bio Pharma Buffer Product and Services
2.8.4 Promega Corporation Bio Pharma Buffer Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Promega Corporation Recent Developments/Updates
2.9 Hamilton Company
2.9.1 Hamilton Company Details
2.9.2 Hamilton Company Major Business
2.9.3 Hamilton Company Bio Pharma Buffer Product and Services
2.9.4 Hamilton Company Bio Pharma Buffer Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Hamilton Company Recent Developments/Updates
2.10 XZL BIO-TECHNOLOGY
2.10.1 XZL BIO-TECHNOLOGY Details
2.10.2 XZL BIO-TECHNOLOGY Major Business
2.10.3 XZL BIO-TECHNOLOGY Bio Pharma Buffer Product and Services
2.10.4 XZL BIO-TECHNOLOGY Bio Pharma Buffer Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 XZL BIO-TECHNOLOGY Recent Developments/Updates
2.11 SRL
2.11.1 SRL Details
2.11.2 SRL Major Business
2.11.3 SRL Bio Pharma Buffer Product and Services
2.11.4 SRL Bio Pharma Buffer Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 SRL Recent Developments/Updates
3 Competitive Environment: Bio Pharma Buffer by Manufacturer
3.1 Global Bio Pharma Buffer Sales Quantity by Manufacturer (2020-2025)
3.2 Global Bio Pharma Buffer Revenue by Manufacturer (2020-2025)
3.3 Global Bio Pharma Buffer Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Bio Pharma Buffer by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Bio Pharma Buffer Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Bio Pharma Buffer Manufacturer 麻豆原创 Share in 2024
3.5 Bio Pharma Buffer 麻豆原创: Overall Company Footprint Analysis
3.5.1 Bio Pharma Buffer 麻豆原创: Region Footprint
3.5.2 Bio Pharma Buffer 麻豆原创: Company Product Type Footprint
3.5.3 Bio Pharma Buffer 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Bio Pharma Buffer 麻豆原创 Size by Region
4.1.1 Global Bio Pharma Buffer Sales Quantity by Region (2020-2031)
4.1.2 Global Bio Pharma Buffer Consumption Value by Region (2020-2031)
4.1.3 Global Bio Pharma Buffer Average Price by Region (2020-2031)
4.2 North America Bio Pharma Buffer Consumption Value (2020-2031)
4.3 Europe Bio Pharma Buffer Consumption Value (2020-2031)
4.4 Asia-Pacific Bio Pharma Buffer Consumption Value (2020-2031)
4.5 South America Bio Pharma Buffer Consumption Value (2020-2031)
4.6 Middle East & Africa Bio Pharma Buffer Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Bio Pharma Buffer Sales Quantity by Type (2020-2031)
5.2 Global Bio Pharma Buffer Consumption Value by Type (2020-2031)
5.3 Global Bio Pharma Buffer Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Bio Pharma Buffer Sales Quantity by Application (2020-2031)
6.2 Global Bio Pharma Buffer Consumption Value by Application (2020-2031)
6.3 Global Bio Pharma Buffer Average Price by Application (2020-2031)
7 North America
7.1 North America Bio Pharma Buffer Sales Quantity by Type (2020-2031)
7.2 North America Bio Pharma Buffer Sales Quantity by Application (2020-2031)
7.3 North America Bio Pharma Buffer 麻豆原创 Size by Country
7.3.1 North America Bio Pharma Buffer Sales Quantity by Country (2020-2031)
7.3.2 North America Bio Pharma Buffer Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Bio Pharma Buffer Sales Quantity by Type (2020-2031)
8.2 Europe Bio Pharma Buffer Sales Quantity by Application (2020-2031)
8.3 Europe Bio Pharma Buffer 麻豆原创 Size by Country
8.3.1 Europe Bio Pharma Buffer Sales Quantity by Country (2020-2031)
8.3.2 Europe Bio Pharma Buffer Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Bio Pharma Buffer Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Bio Pharma Buffer Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Bio Pharma Buffer 麻豆原创 Size by Region
9.3.1 Asia-Pacific Bio Pharma Buffer Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Bio Pharma Buffer Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Bio Pharma Buffer Sales Quantity by Type (2020-2031)
10.2 South America Bio Pharma Buffer Sales Quantity by Application (2020-2031)
10.3 South America Bio Pharma Buffer 麻豆原创 Size by Country
10.3.1 South America Bio Pharma Buffer Sales Quantity by Country (2020-2031)
10.3.2 South America Bio Pharma Buffer Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Bio Pharma Buffer Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Bio Pharma Buffer Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Bio Pharma Buffer 麻豆原创 Size by Country
11.3.1 Middle East & Africa Bio Pharma Buffer Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Bio Pharma Buffer Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Bio Pharma Buffer 麻豆原创 Drivers
12.2 Bio Pharma Buffer 麻豆原创 Restraints
12.3 Bio Pharma Buffer Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Bio Pharma Buffer and Key Manufacturers
13.2 Manufacturing Costs Percentage of Bio Pharma Buffer
13.3 Bio Pharma Buffer Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Bio Pharma Buffer Typical Distributors
14.3 Bio Pharma Buffer Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Avantor
Alfa Aesar (Thermo Fisher)
Merck
Lonza
Bio-Rad
BD
GE Healthcare
Promega Corporation
Hamilton Company
XZL BIO-TECHNOLOGY
SRL
听
听
*If Applicable.
